Richard T. Schumacher, CEO of Pressure BioSciences, Inc., Returns to Uptick Newswire's "Stock Day" Podcast with Everett Jolly to Review Significant Achievements in 2017 and Discuss Exciting Developments Expected in 2018
Phoenix, March 13, 2018 (GLOBE NEWSWIRE) -- Richard T. Schumacher, President and CEO of Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"), a leader in the development and sale of innovative, broadly enabling, high pressure-based instruments and related consumables for the worldwide life sciences industry, was recently interviewed on Uptick Newswire’s “Stock Day” podcast with Mr. Everett Jolly.
“Throughout 2017, Pressure BioSciences had a remarkable number of initiatives going on both front-and-center as well as behind the scenes. Some of these programs came to fruition in 2017, some have begun to emerge in early 2018, and some seem destined to blossom later this year,” said Mr. Jolly. “To that end, the Company held a business update for investors and other stakeholders in late December 2017, at which all PBIO officers, the company’s Board Chairman, and representatives of BaroFold (the company PBIO acquired in December 2017) spoke about their specific initiatives and took questions from the attendees. Afterwards, on January 23, 2018, Ric joined us for a Stock Day Podcast. Since that time, the company has seen its stock increase more than $1.50 per share, or about 50%.”
“For the past nine years, we’ve basically had one full-time sales person in the field, yet we have grown from a small company selling just a handful of our novel, enabling instruments to now having 300 instruments placed, resulting in about $2 million in annual sales, with solid year over year revenue growth trends,” noted Mr. Schumacher. “We believe we have set the table to facilitate even greater revenue growth with the deployment of an experienced, trained, and dedicated field sales team, the acquisition of the BaroFold, Inc. assets – including 8 important patents that integrate well with our own seventeen patents, and our very recently announced co-marketing and distribution relationship with ISS, Inc.”
“With these new initiatives firmly in place, a priceless global customer base, a newly released next-generation instrument, additional key opinion leader customers, and our new BaroFold and Ultra Shear Technology (UST) programs, we look forward with excitement to 2018, which we believe should be a solid year of growth and expansion.”
To listen to the full interview please click here to the following link: https://upticknewswire.com/wp-content/uploads/2018/03/Uptick-Network-PBIO-Interview-3-8-18.mp3
For more information on discussed topics, please click the following links:
Replay of December 20, 2017 Business Update
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired PreEMT technology from BaroFold, Inc. to allow immediate entry into the biologics contract research services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.
Forward Looking Statements
Statements contained in this press release regarding PBI's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2016, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.
About Uptick Newswire and the “Stock Day” Podcast
Uptick Newswire is a private company reaching out to the masses keeping investors and shareholders up to date on company news and bringing transparency to the undervalued, undersold, micro-cap stocks of the market and is the sole producer of the Uptick Network “Stock Day” Podcast. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire and has recently launched the Video Interview Studio located in Phoenix, Arizona with its new host Kathryn Donnelly.
Source: Uptick Newswire
For more information about PBIO and this press release, please click on the following website link: http://www.pressurebiosciences.com Please visit PBIO on Facebook, LinkedIn, and Twitter Investor Contacts: Pressure BioSciences, Inc. Richard T. Schumacher President & CEO Nathan P. Lawrence, Ph.D. VP of Marketing and Sales (508) 230-1828 (T)Source: Pressure BioSciences, Inc.
Released March 13, 2018